Naviter Wealth Trims Johnson & Johnson Stake

Institutional investor reduces holdings in pharmaceutical giant

Apr. 11, 2026 at 10:08am

Got story updates? Submit your updates here. ›

An extreme close-up of the heavy, industrial machinery and mechanisms of a large bank vault, conveying a sense of financial security and stability without using any literal currency or symbols.Institutional investors' trading activity in Johnson & Johnson shares provides insights into market sentiment around the healthcare giant.New Brunswick Today

Naviter Wealth LLC, a financial advisory firm, decreased its position in Johnson & Johnson (NYSE: JNJ) by 12.1% in the fourth quarter, according to a recent SEC filing. The fund now owns 20,030 shares of the company's stock, valued at $4.145 million.

Why it matters

Johnson & Johnson is one of the world's largest and most diversified healthcare companies, with a significant presence in pharmaceuticals, medical devices, and consumer products. Institutional investors' trading activity in JNJ shares can provide insights into market sentiment and expectations around the company's performance.

The details

According to the 13F filing, Naviter Wealth sold 2,764 shares of Johnson & Johnson during the fourth quarter. The firm now holds a total of 20,030 shares, down from 22,794 shares at the end of the previous quarter. Johnson & Johnson's stock price has seen strong performance over the past year, rising from around $146 per share to over $238 per share as of the most recent trading session.

  • Naviter Wealth filed its 13F report for the fourth quarter of 2025 on April 11, 2026.
  • The firm decreased its Johnson & Johnson holdings during the three-month period ending December 31, 2025.

The players

Naviter Wealth LLC

A financial advisory firm that manages investments for institutional and individual clients.

Johnson & Johnson

A multinational healthcare company that develops, manufactures, and markets pharmaceutical, medical device, and consumer products.

Got photos? Submit your photos here. ›

The takeaway

Naviter Wealth's reduction in its Johnson & Johnson position suggests the firm may have a more cautious outlook on the healthcare giant's near-term prospects, even as the stock has seen strong gains over the past year. Investors will likely monitor institutional trading activity in JNJ shares for further insights into market sentiment around the company.